Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2004, p. 966-975, Vol. 24, No. 3
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.3.966-975.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Caroline A. Beeton,1 Jorgen Jensen,2 Wayne A. Phillips,3 and Peter R. Shepherd1*
Department of Biochemistry and Molecular Biology, University College London, London WC1E 6BT, United Kingdom,1 Department of Physiology, National Institute of Occupational Health, 0033 Oslo, Norway,2 Peter MacCallum Cancer Institute, Melbourne, Victoria 8006, Australia3
Received 19 May 2003/ Returned for modification 26 June 2003/ Accepted 3 November 2003
One potentially important mechanism for regulating class Ia phosphoinositide 3-kinase (PI 3-kinase) activity is autophosphorylation of the p85
adapter subunit on Ser608 by the intrinsic protein kinase activity of the p110 catalytic subunit, as this downregulates the lipid kinase activity in vitro. Here we investigate whether this phosphorylation can occur in vivo. We find that p110
phosphorylates p85
Ser608 in vivo with significant stoichiometry. However, p110ß is far less efficient at phosphorylating p85
Ser608, identifying a potential difference in the mechanisms by which these two isoforms are regulated. The p85
Ser608 phosphorylation was increased by treatment with insulin, platelet-derived growth factor, and the phosphatase inhibitor okadaic acid. The functional effects of this phosphorylation are highlighted by mutation of Ser608, which results in reduced lipid kinase activity and reduced association of the p110
catalytic subunit with p85
. The importance of this phosphorylation was further highlighted by the finding that autophosphorylation on Ser608 was impaired, while lipid kinase activity was increased, in a p85
mutant recently discovered in human tumors. These results provide the first evidence that phosphorylation of Ser608 plays a role as a shutoff switch in growth factor signaling and contributes to the differences in functional properties of different PI 3-kinase isoforms in vivo.
Present address: Ludwig Institute for Cancer Research, London W1W 7BS, United Kingdom.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|